
PRESS KIT
Summary
AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease.
Technology Overview
AbCellera’s full-stack, AI-powered drug discovery platform, which integrates modern technologies from engineering, microfluidics, single-cell analysis, high-throughput genomics, machine learning, and hyper-scale data science, empowers drug developers of all sizes to move quickly, reduce costs, and tackle the toughest problems in drug development.

Quotes



Notable Press Mentions

2021 EY Entrepreneur Of The Year Builds Biotech Powerhouse

AbCellera Acquires Tetragenetics, Announces Multi-year Partnership with Moderna

AbCellera to Collaborate with Tachyon, EQRx on Therapeutic Antibodies for Cancer

Vancouver Headquarter Groundbreaking and Manufacturing

Gilead again Partners for Multitarget Deal

Novartis Inks 10-target antibody discovery deal with AbCellera
Follow Us